Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

BACKGROUND: Patients with primary refractory and relapsed neuroblastoma have a poor prognosis since safe and effective chemotherapies for these patients are currently limited. The development of new chemotherapy regimens for these patients is imperative to improve survival outcomes. METHODS: We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Imaya, Masayuki, Muramatsu, Hideki, Narita, Atsushi, Yamamori, Ayako, Wakamatsu, Manabu, Yoshida, Taro, Miwata, Shunsuke, Narita, Kotaro, Ichikawa, Daisuke, Hamada, Motoharu, Nishikawa, Eri, Kawashima, Nozomu, Nishio, Nobuhiro, Kojima, Seiji, Takahashi, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089216/
https://www.ncbi.nlm.nih.gov/pubmed/35233973
http://dx.doi.org/10.1002/cam4.4529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089216/
https://www.ncbi.nlm.nih.gov/pubmed/35233973
http://dx.doi.org/10.1002/cam4.4529

Ejemplares similares